Health Hazard Assessments for Effects Other than Cancer
Reference Dose for Oral Exposure (RfD) (PDF) (15 pp, 125 K)
last updated: 09/26/1988
|System||RfD (mg/kg-day)||Basis||PoD||Composite UF||Confidence|
|Reproductive||3 x 10-3||Inflammation of the prostate||
: 3 x 10-1
Reference Concentration for Inhalation Exposure (RfC) (PDF) (15 pp, 125 K)
Not assessed under the IRIS Program.
Weight of Evidence for Cancer (PDF) (15 pp, 125 K)
last updated: 08/01/1990
|WOE Characterization||Framework for WOE Characterization|
|C (Possible human carcinogen)||Guidelines for Carcinogen Risk Assessment (US EPA, 1986)|
- Hepatocellular adenomas and carcinomas in female B6C3F1 mice.
- This may be a synopsis of the full weight-of-evidence narrative.
Oral Slope Factor:
1.1 x10 -1 per mg/kg-day
Drinking Water Unit Risk: 3.1 x10 -6 per µg/L
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Hepatic
Tumor type(s): Liver, hepatocellular carcinoma, and adenomas (combined) (U.S. DOD, 1984)
Not Assessed under the IRIS Program.
Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) is being reassessed.
Assessment Manager(s): Louis D'Amico (firstname.lastname@example.org)
|Step||Assessment Materials Released to the Public||Release Date||Public Meeting Date|
|1||Problem Formulation Materials||N/A||N/A|
|1||Preliminary Assessment Materials||08/2013||12/2013|
|4||Public Comment Draft||03/2016||05/2016|
|4||Peer Review Draft||09/2016||12/2016|
|7||Post Final Assessment||TBD|
Please note: Any future dates displayed under Release Date are estimates and subject to change.
You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.